EUVIMEDEUVIMED entdecken
Multizentrische Studie

Gut microbiota diversity in patients with ESCC: associations with esophagectomy, the tumor immune microenvironment, and nivolumab response

Yuho Ebata, Eiji Oki, Qingjiang Hu, Hirofumi Hasuda, Tetsuro Kawazoe, Sho Nambara, Yasuo Tsuda, Tomonori Nakanoko, Koji Ando, Yasue Kimura, Kentaro Sawada, Riu Yamashita und 8 weitere

Esophagus · 2026-07 · 23 (3) · 523-534

DOI: 10.1007/s10388-026-01205-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Esophagus, online erschienen am 20.04.2026. Verfasst von Yuho Ebata und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. Hauptthemen laut MEDLINE: Esophagectomy, Tumor Microenvironment, Nivolumab, Esophageal Neoplasms. Die Arbeit nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: Esophagectomy may alter gut microbiota, a key regulator of antitumor immunity and immune checkpoint inhibitor (ICI) efficacy; however, its impact in patients with esophageal squamous cell carcinoma (ESCC) remains unclear. This study evaluated the association between the tumor immune microenvironment (TIME) and gut microbiota and also investigated gut microbiota composition in relation to nivolumab response in patients with ESCC. METHODS: Two cohorts were analyzed. In Cohort 1 (n = 18), fecal samples collected before and three months after esophagectomy were analyzed alongside TIME profiling, and patients were classified as hot or cold tumors based on CD8+ T-cell infiltration and PD-L1 expression. In Cohort 2 (n = 35), the relationship between baseline gut microbiota and nivolumab response was assessed using a retrospective analysis of a prospectively collected multicenter cohort. RESULTS: Patients with hot tumors exhibited higher microbial alpha diversity than those with cold tumors. Before esophagectomy, cold tumors showed enrichment of Streptococcus, Veillonella, Haemophilus, and Gemella, whereas hot tumors were enriched in Flavonifractor and Phascolarctobacterium; these differences disappeared postoperatively, indicating surgery-associated compositional shifts. In Cohort 2, higher alpha diversity was associated with favorable nivolumab response, while patients with Streptococcus- or Veillonella-enriched microbiota more frequently had residual tumors and poor outcomes. CONCLUSION: Gut microbiota diversity was associated with the tumor immune microenvironment and nivolumab response in patients with esophageal cancer. Esophagectomy was also associated with alterations in gut microbial composition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EsophagectomyTumor MicroenvironmentNivolumabEsophageal NeoplasmsGastrointestinal MicrobiomeEsophageal Squamous Cell CarcinomaHumansFemaleMaleAgedRetrospective StudiesMiddle AgedImmune Checkpoint InhibitorsCohort StudiesTreatment OutcomeAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

16S rRNA sequencingEsophageal squamous cell carcinomaGut microbiotaNivolumabTumor microenvironment

Substanzen

NivolumabImmune Checkpoint InhibitorsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. oki.eiji.857@m.kyushu-u.ac.jp.
  • Department of Surgery, Kyushu University Beppu Hospital, Oita, Japan.
  • Department of Gastroenterological Surgery and Clinical Research Institute, Kyushu Medical Center, Fukuoka, Japan.
  • Department of Gastroenterological Surgery, National Hospital Organization Kyushu Cancer, Fukuoka, Japan.
  • Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan.

Zitieren

APA

Ebata, Y., Oki, E., Hu, Q., Hasuda, H., Kawazoe, T., Nambara, S., Tsuda, Y., Nakanoko, T., Ando, K., Kimura, Y., Sawada, K., Yamashita, R., Horasawa, S., Fujisawa, T., Bando, H., Nakamura, Y., Yoshino, T., Yokota, H., Ohno, H., & Yoshizumi, T. (2026). Gut microbiota diversity in patients with ESCC: associations with esophagectomy, the tumor immune microenvironment, and nivolumab response. Esophagus, 23(3), 523-534. https://doi.org/10.1007/s10388-026-01205-3

Vancouver

Ebata Y, Oki E, Hu Q, Hasuda H, Kawazoe T, Nambara S, et al. Gut microbiota diversity in patients with ESCC: associations with esophagectomy, the tumor immune microenvironment, and nivolumab response. Esophagus. 2026;23(3):523-534. doi:10.1007/s10388-026-01205-3

BibTeX
@article{Ebata2026,
  author = {Ebata, Yuho and Oki, Eiji and Hu, Qingjiang and Hasuda, Hirofumi and Kawazoe, Tetsuro and Nambara, Sho and Tsuda, Yasuo and Nakanoko, Tomonori and Ando, Koji and Kimura, Yasue and Sawada, Kentaro and Yamashita, Riu and Horasawa, Satoshi and Fujisawa, Takao and Bando, Hideaki and Nakamura, Yoshiaki and Yoshino, Takayuki and Yokota, Haruka and Ohno, Hiroshi and Yoshizumi, Tomoharu},
  title = {Gut microbiota diversity in patients with ESCC: associations with esophagectomy, the tumor immune microenvironment, and nivolumab response},
  journal = {Esophagus},
  year = {2026},
  volume = {23},
  number = {3},
  pages = {523--534},
  doi = {10.1007/s10388-026-01205-3}
}
Kostenlos starten →